Figure 4
Population attributable benefit (PAB) from the use of any CV medication (med), blood pressure (BP)-lowering medication, blood glucose-lowering medication, and anti-thrombotic medications in the prevention of CVD and mortality in participants with BMI ≥30 kg/m2. CI, confidence interval.

Population attributable benefit (PAB) from the use of any CV medication (med), blood pressure (BP)-lowering medication, blood glucose-lowering medication, and anti-thrombotic medications in the prevention of CVD and mortality in participants with BMI ≥30 kg/m2. CI, confidence interval.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close